Meeting
2020 Genitourinary Cancers Symposium
NIVOREN GETUG-AFU 26 translational study: Association of PD-1, AXL, and PBRM-1 with outcomes in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N).
Presenter
Yann-Alexandre Vano, M.D.
Department of Medical Oncology, Georges Pompidou Hospital, University Paris Descartes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Rapid Oral Abstract Session
Session Title
Rapid Abstract Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 618)
Abstract #
618
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Health-related quality of life (HRQoL) with nivolumab (NIVO) subcutaneous (SC) or intravenous (IV) in patients (pts) with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have received prior therapy in the phase 3 CheckMate 67T trial.
Speaker: Saby George, MD, FACP
Videos & Slides
2022 ASCO Annual Meeting
Subcutaneous nivolumab versus intravenous nivolumab in patients with previously treated, advanced, or metastatic clear cell renal cell carcinoma.
Speaker: Matias Rodrigo Chacon, MD
Videos & Slides
2020 ASCO Virtual Scientific Program
Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.
Speaker: Miriam Ficial, MD
Videos & Slides
2024 ASCO Annual Meeting
Subcutaneous (SC) nivolumab (NIVO) vs intravenous (IV) NIVO in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Safety and patient-reported outcomes (PROs) of the randomized phase 3 CheckMate 67T trial.
Speaker: Maria T. Bourlon, MD, MSc